120 related articles for article (PubMed ID: 36610379)
1. Missed opportunities in the real-world genetic testing in BRCA gene variant carriers with cancers meeting NCCN criteria.
Lee SS; Rajeev P; Finning S; Oh C; Pothuri B
Gynecol Oncol; 2023 Mar; 170():32-37. PubMed ID: 36610379
[TBL] [Abstract][Full Text] [Related]
2. Beyond BRCA: Patterns of risk-reducing surgery for non-BRCA, homologous recombination repair pathway gene variant carriers.
Lee SS; Karpel HC; Oh C; Smith J; Pothuri B
Gynecol Oncol; 2023 Mar; 170():234-240. PubMed ID: 36724586
[TBL] [Abstract][Full Text] [Related]
3. Rate of BRCA mutation in patients tested under NCCN genetic testing criteria.
Beck AC; Yuan H; Liao J; Imperiale P; Shipley K; Erdahl LM; Sugg SL; Weigel RJ; Lizarraga IM
Am J Surg; 2020 Jan; 219(1):145-149. PubMed ID: 31255259
[TBL] [Abstract][Full Text] [Related]
4. Adherence to National Comprehensive Cancer Network Guidelines for
Bobbili P; Olufade T; DerSarkissian M; Shenolikar R; Yu H; Duh MS; Tung N
Hered Cancer Clin Pract; 2020; 18():13. PubMed ID: 32518611
[TBL] [Abstract][Full Text] [Related]
5.
Kansu B; Gardner J; Price-Tate R; Murch O; Murray A
J Obstet Gynaecol; 2021 Aug; 41(6):962-965. PubMed ID: 33228436
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of family history in individuals with heterozygous BRCA pathogenic variants diagnosed with breast or ovarian cancer in a single center in Italy.
Negri S; De Ponti E; Sina FP; Sala E; Dell'Oro C; Roversi G; Lazzarin S; Delle Marchette M; Inzoli A; Toso C; Fumagalli S; Campanella M; Kotsopoulos J; Fruscio R
Mol Genet Genomic Med; 2022 Dec; 10(12):e2071. PubMed ID: 36307994
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Kemp Z; Turnbull A; Yost S; Seal S; Mahamdallie S; Poyastro-Pearson E; Warren-Perry M; Eccleston A; Tan MM; Teo SH; Turner N; Strydom A; George A; Rahman N
JAMA Netw Open; 2019 May; 2(5):e194428. PubMed ID: 31125106
[TBL] [Abstract][Full Text] [Related]
8. Preoperative genetic testing affects surgical decision making in breast cancer patients.
Lokich E; Stuckey A; Raker C; Wilbur JS; Laprise J; Gass J
Gynecol Oncol; 2014 Aug; 134(2):326-30. PubMed ID: 24910453
[TBL] [Abstract][Full Text] [Related]
9. BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines.
Chun DS; Berse B; Venne VL; DuVall SL; Filipski KK; Kelley MJ; Meyer LJ; Icardi MS; Lynch JA
Fam Cancer; 2017 Jan; 16(1):41-49. PubMed ID: 27589855
[TBL] [Abstract][Full Text] [Related]
10. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.
Sharma P; Klemp JR; Kimler BF; Mahnken JD; Geier LJ; Khan QJ; Elia M; Connor CS; McGinness MK; Mammen JM; Wagner JL; Ward C; Ranallo L; Knight CJ; Stecklein SR; Jensen RA; Fabian CJ; Godwin AK
Breast Cancer Res Treat; 2014 Jun; 145(3):707-14. PubMed ID: 24807107
[TBL] [Abstract][Full Text] [Related]
11. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.
Grindedal EM; Heramb C; Karsrud I; Ariansen SL; Mæhle L; Undlien DE; Norum J; Schlichting E
BMC Cancer; 2017 Jun; 17(1):438. PubMed ID: 28637432
[TBL] [Abstract][Full Text] [Related]
12. The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
Sorscher S; Ansley K; Delaney SD; Ramkissoon S
Breast Cancer Res Treat; 2020 Apr; 180(2):511-514. PubMed ID: 32040686
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
[TBL] [Abstract][Full Text] [Related]
14. Adherence to NCCN Guidelines for Genetic Testing in Breast Cancer Patients: Who Are We Missing?
Alberty-Oller JJ; Weltz S; Santos A; Pisapati K; Ru M; Weltz C; Schmidt H; Port E
Ann Surg Oncol; 2021 Jan; 28(1):281-286. PubMed ID: 32918176
[TBL] [Abstract][Full Text] [Related]
15. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
[TBL] [Abstract][Full Text] [Related]
16. Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer.
Barcenas CH; Shafaee MN; Sinha AK; Raghavendra A; Saigal B; Murthy RK; Woodson AH; Arun B
J Natl Compr Canc Netw; 2018 May; 16(5):518-524. PubMed ID: 29752326
[No Abstract] [Full Text] [Related]
17. Promoters of BRCA testing under insurance coverage for non-metastatic breast cancer patients in Japan: a retrospective cohort study.
Taji T; Odan N; Kataoka Y; Ikeda M; Yamaguchi A; Suzuki E; Suwa H
Breast Cancer; 2023 Mar; 30(2):309-314. PubMed ID: 36547869
[TBL] [Abstract][Full Text] [Related]
18. Age at diagnosis may trump family history in driving BRCA testing in a population of breast cancer patients.
Vig HS; McCarthy AM; Liao K; Demeter MB; Fredericks T; Armstrong K
Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1778-85. PubMed ID: 23917453
[TBL] [Abstract][Full Text] [Related]
19. Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center.
Mittal A; Deo SVS; Gogia A; Batra A; Kumar A; Bhoriwal S; Deb KS; Dhamija E; Thulkar S; Ramprasad VL; Olopade O; Pramanik R
Ann Surg Oncol; 2022 Feb; 29(2):1423-1432. PubMed ID: 34601666
[TBL] [Abstract][Full Text] [Related]
20. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
Sorscher S; Ramkissoon S
Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
